Evidence map›Paper›PMID 39951175›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Neurologic features in hospitalized patients with COVID-19: a prospective cohort in a catalan hospital.

Oriol Barrachina-Esteve, A Anguita, A Reverter, J Espinosa, C Lafuente, M Rubio-Roy, M Crosas, C Vila-Sala, C Acero, M Navarro and 4 more

Abstract read
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Oriol Barrachina-EsteveDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain. Oriol.Barrachina@autonoma.cat.ORCID http://orcid.org/0000-0002-8519-0784
A AnguitaDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
A ReverterDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
J EspinosaDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
C LafuenteDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
M Rubio-RoyDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
M CrosasDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
C Vila-SalaDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
C AceroDepartment of Ophthalmology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
M NavarroDepartment of Infectious Diseases, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
D CánovasDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
G RiberaDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
M JodarDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.
J EstelaDepartment of Neurology, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute Foundation (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo study the prevalence and timing of neurological manifestations, including cognitive involvement, in patients hospitalized for Coronavirus disease 2019 (COVID-19). To analyze the pathogenic mechanisms and any association they have with disease severity.

methodsLongitudinal cohort study with prospective follow-up of patients who required hospitalization. Patients under 65 who had no pre-existing cognitive impairment and did not require an ICU stay were evaluated 3 and 12 months after discharge using a battery of neuropsychological tests.

resultsOf 205 patients hospitalized for COVID-19, 153 (74.6%) presented with neurological manifestations. The most frequent were myalgia (32.7%), headache (31.7%), dysgeusia (29.2%), and anosmia (24.9%). Patients with more severe illness at the time of hospitalization presented fewer neurological manifestations. Of the 62 patients who underwent neuropsychological examination 3 months after discharge, 22.6% had impaired attention, 19.4% impaired working memory, 16.1% impaired learning and retrieval, 9.7% impaired executive functions, and 8.2% impaired processing speed. Patients with anosmia also presented with more headache (OR 5.45; p < 0.001) and greater risk of working memory impairment (OR 5.87; p 0.03). At follow-up 12 months after hospital discharge, 14.3% of patients still showed impaired attention, 2.4% impaired working memory, 2.5% impaired executive functions, and 2.5% impaired processing speed. DISCUSSION: Neurological manifestations are common in patients hospitalized for COVID-19 regardless of severity. The high prevalence of anosmia and its association with headache and working memory impairment at 3 months, suggest potential direct or indirect damage to the prefrontal cortex via invasion of the olfactory bulb by COVID-19.

Indexed as

Cognitive DysfunctionCOVID-19Nervous System DiseasesAdultAgedAnosmiaFemaleHeadacheHospitalizationHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsProspective StudiesSpainClinical neurologyCognitive disordersCOVID-19Neurovirology

Identifiers

PMID39951175
PMCPMC11920300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.